Meitheal Pharmaceuticals has Nelarabine Injection Now Available

Meitheal Pharmaceuticals (Meitheal) is pleased to announce that we have launched Nelarabine Injection, 250 mg per 50 mL, in a single-dose vial.

Meitheal will offer Nelarabine Injection in a carton of 6 vials.


Nelarabine Injection is a nucleoside metabolic Inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens link.


Learn more about who we are and what we do at